Company Biodyne Co., Ltd.

Equities

A314930

KR7314930009

Medical Equipment, Supplies & Distribution

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Sales per Business

Sales per region

EPS Revisions

Annual profits - Rate of surprise

Sector Diagnostic & Testing Substances

End-of-day quote Korea S.E. Other stock markets 18:00:00 2024-06-11 EDT			5-day change	1st Jan Change
15,500 ^KRW	+5.66%		+36.93%	+19.23%

2023	Biodyne Co., Ltd.(KOSDAQ:A314930) added to S&P Global BMI Index	CI
2023	Biodyne Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI

Biodyne Co Ltd is a Korea-based company mainly engaged in the production and sales of liquid based cytology (LBC) diagnostic reagent kits. The Company produces and sells LBC diagnostic equipment and diagnostic reagent kits. The Company's LBC equipment include PATHPLORER AUTO, PATHPLORER 4.7, PATHPLORER 4.63 and PATHPLORER ECO. The Company sells its products in domestic and overseas markets such as Japan, Russia, Portugal and Thailand.

KRW in Million	2022	Weight	2023	Weight	Delta
Cancer Diagnosis Solutions - Merchandise 100.0 %	-	-	4,089	100.0 %	-

KRW in Million	2022	Weight	2023	Weight	Delta
South Korea 30.1 %	1,186	9.7 %	1,229	30.1 %	+3.60%
Japan 28.8 %	1,193	9.8 %	1,177	28.8 %	-1.31%
Europe 28.0 %	1,065	8.7 %	1,143	28.0 %	+7.34%
Others 13.2 %	8,766	71.8 %	539	13.2 %	-93.85%

Managers	Title	Age	Since
Wook-Bin Im CEO	Chief Executive Officer	50	-
Gwang-Sik Shin DFI	Director of Finance/CFO	51	-
Ja-Min Lee CTO	Chief Tech/Sci/R&D Officer	49	-
Woo-Seok Jo COO	Chief Operating Officer	53	-
Yong-Jin Jung AUD	Comptroller/Controller/Auditor	49	-

Members of the board	Title	Age	Since
Jong-Hoon Lee BRD	Director/Board Member	40	-
Wook-Bin Im CEO	Chief Executive Officer	50	-
Gwang-Sik Shin DFI	Director of Finance/CFO	51	-
Woo-Seok Jo COO	Chief Operating Officer	53	-
Ja-Min Lee CTO	Chief Tech/Sci/R&D Officer	49	-
Jae-Man Bae BRD	Director/Board Member	52	-

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	29,764,103	12,201,203 ( 40.99 %)	287,343 ( 0.9654 %)	40.99 %

Name	Equities	%	Valuation
Wook-Bin Im 42.64 %	13,180,239	42.64 %	88 M ₩
BIODYNE CO., LTD. 4.648 %	1,436,715	4.648 %	10 M ₩
Jung-wan Hong 2.426 %	750,000	2.426 %	5 M ₩
Woo-Seok Jo 0.6826 %	211,000	0.6826 %	1 M ₩
Jeong-Bin Lim 0.2146 %	66,345	0.2146 %	441 805 ₩
Geun-ho Yang 0.0265 %	8,200	0.0265 %	54 605 ₩
Dimensional Fund Advisors Ltd. 0.007570 %	2,340	0.007570 %	15 583 ₩
Yu-ra Go 0.006065 %	1,875	0.006065 %	12 486 ₩
DFA Australia Ltd. 0.001779 %	550	0.001779 %	3 663 ₩

Name	Equities	%	Valuation
BIODYNE CO., LTD. 4.65%	1,436,715	4.65%	9,567,373 $

BIODYNE Co., Ltd.

24-4 Achasan-ro 5-gil Seongdong-gu

04793, Seoul

http://www.biodyne.asia

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

15,500 KRW

Average target price

260,000 KRW

Spread / Average Target

+1,577.42%

Consensus

Estimates Revisions

Company calendar

Healthcare

Healthcare Services

Healthcare Equipment & Supplies

Medical Equipment, Supplies & Distribution

Diagnostic & Testing Substances

	1st Jan change	Capi.
BIODYNE CO., LTD.	+19.23%	338M
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-2.58%	8.27B
DIASORIN S.P.A.	+8.22%	5.81B
LANTHEUS HOLDINGS, INC.	+29.76%	5.58B
AUTOBIO DIAGNOSTICS CO., LTD.	-15.77%	3.85B
ANDON HEALTH CO., LTD.	+12.42%	2.71B
10X GENOMICS, INC.	-61.85%	2.56B
VITROLIFE AB	-6.57%	2.42B
MYRIAD GENETICS, INC.	+23.09%	2.13B
GUANGZHOU WONDFO BIOTECH CO.,LTD	-9.25%	1.77B

Diagnostic & Testing Substances